
In a 24-week study at Odawara Hospital, hypertensive patients with diabetes or CKD saw significant blood pressure and NT-proBNP reductions using Esaxerenone (ESAX). Pre-HFpEF patients had greater improvements in cardiac function (E/e' ratio, GLS), with 30% improving to stage A. Both HFpEF and pre-HFpEF groups benefited, suggesting ESAX’s value in targeting early heart failure to prevent disease progression.
Like
Save
Share